Tetraspanin proteins form signaling complexes between them and with other membrane proteins and modulate cell adhesion and migration properties. The surface expression of several tetraspanin antigens (CD9, CD37, CD53, CD63, and CD81), and their interacting proteins (CD19, CD21, and HLA-DR) were analyzed during normal B-cell maturation and compared to a group of 67 B-cell neoplasias. Three patterns of tetraspanin expression were identified in normal B cells. The first corresponded to bone marrow CD10 þ B-cell precursors (BCP) which showed high expression of CD81 and CD9, low reactivity for CD53 and negativity for CD37. CD10
Introduction
Tetraspanin proteins are a group of structurally related membrane proteins involved in cell adhesion 1-7 motility [8] [9] [10] [11] [12] [13] [14] [15] [16] and apoptosis; 17 the exact mechanisms through which they modulate these processes remains unknown. They have four common transmembrane domains with four, six or eight cysteine residues and a CCG motif in the largest extracellular loop. 18, 19 In all, 25 members have been identified so far. Although the expression of some of these molecules is limited almost exclusively to lymphoid or myeloid cells (eg CD37), most tetraspanin are widely expressed in many non,hematopoietic cell types (eg CD9, CD63 and CD81). 20, 21 Mammalian cells simultaneously express several tetraspanin antigens, which might form specific complexes on the plasma membrane. 15, 18, [22] [23] [24] On the cell surface, tetraspanin antigens are present either as free molecules or through interaction with other proteins. 25, 26 These interacting proteins include other tetraspanins, integrinsFparticularly those with the b1 subunit 22, [27] [28] [29] [30] FHLA class II moleculesFeg HLA DR [31] [32] [33] -, CD19, 34, 35 the T-cell receptor 36, 37 and several other members of the immunoglobulin superfamily. 38 As an example, CD81 binds to a CD19/CD21 complex on B-cells, 39 as well as to CD9 and CD82. 35 The diversity in the composition of tetraspanins, and those proteins interacting with the tetraspanin-containing membrane complexes allows for a larger plasticity of their signaling properties. 15, 23, 24 Overall, it is likely that the pattern of expression of tetraspanin proteins is a major determining factor in the specific adhesion and homing properties of a cell, 40 and that changes in this profile will be followed by a redistribution of the cell within the organism in terms of its developmental stage or functional state. As a result of the complex pattern of tetraspanin gene expression, it is very likely that the adhesion and migration properties of tumor cells are also influenced by the alteration in the composition of cell-specific tetraspanin protein complexes.
Abnormal levels of tetraspanin antigens have been identified in many different types of carcinomas. 41, 42 In general, low expression of some individual molecules has been related to a poor prognosis. Accordingly, low levels of CD63 in melanomas 43 as well as in colon carcinomas 42 indicated a higher metastatic potential. Additional correlations between abnormally low levels of tetraspanin molecules and poor prognosis have been reported for CD9 in the lung, 9 oral, 44 cervical 45 and breast carcinomas 8 and for CD82 in the prostate, 12,46,47 breast 48 and lung cancer. 49 Interestingly, re-expression of CD9 50 and CD82 12 in the tumor cells increases their adhesion and subsequently reduces their motility. Regarding CD53, its reduced expression in normal cells is associated with a syndrome very similar to leukocyte adhesion defects, characterized by recurrent infections. 51 In the present study, we have quantitatively analyzed the distribution and the pattern of expression of several tetraspanin antigens in normal and neoplastic human B cells. Our results show a high frequency of aberrant expression of tetraspanin molecules in tumor B cells. Despite this, the overall pattern of expression of these proteins during normal B-cell maturation correlated with the stage of maturation arrest in B-cell neoplasias, which could be of help for diagnostic purposes.
Materials and methods

Controls and patients
Analysis of the expression of tetraspanin molecules and other functionally related surface proteins along the normal B-cell differentiation was performed on a total of 17 normal samples obtained from subjects without any known disease and with normal blood cell counts: six bone marrow (BM) and nine peripheral blood (PB) samples obtained from an identical number of healthy adult volunteers and two reactive lymph node samples. In turn, normal residual plasma cells (PC) were analyzed in three BM samples from an identical number of patients with monoclonal gammopathy of undetermined significance (MGUS).
In addition, a total of 25 BM, 41 PB and one lymph node sample from a total of 67 newly diagnosed untreated patients with clonal B-cell malignancies, were studied. Diagnosis of the different B-cell malignancies was based on clinical, morphologic, immunophenotypic and molecular criteria, according to the WHO classification. þ ; splenic marginal zone lymphoma (SMZL), one; MALT lymphoma, five cases; follicular lymphoma (FL), two patientsFboth being t (14;18) þ ; bcl6 þ diffuse large B-cell lymphoma (DLBCL), one patient; Burkitt's lymphoma, two patientsFone being t (8;14) þ ; multiple myeloma (MM), five patients; and MGUS, five cases. Samples from both the patients and the controls were obtained after informed consent, according to the Ethics Committee of the University Hospital of Salamanca (Salamanca, Spain).
Flow cytometry immunophenotypic studies
All normal and neoplastic PB and BM samples were collected in tubes containing K 3 -ethylenediaminotetraacetic acid (EDTA) as anticoagulant. BM samples were immediately diluted 1/1 (vol/vol) in phosphate-buffered saline (PBS). Lymph node samples were obtained by fine-needle aspiration, according to well-established procedures. Immunophenotypic studies were performed on erythrocyte-lysed samples using wellestablished direct immunofluorescence stain, lyse and then wash procedures. 54 Nucleated cells (1-2 Â 10 6 cells in 100 ml/test) were stained using the following three-and four-color combinations of monoclonal antibodies (MoAb) directly conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridin chlorophyll protein (PerCP) and for four color combinations allophycocyanine (APC): CD63/ CD53/CD19 or CD38; CD9/CD37/CD19 or CD38 and CD21/ CD81/HLA-DR/CD19 or CD38. The source of the MoAb was as follows: CD19 (clone SJ25C1), CD38 (clone HB7) and anti-HLA-DR (clone L243) were purchased from Becton Dickinson Biosciences (-BDB-San José, CA, USA), CD53 (clone HI29) and CD81 (clone JS81) were from PharMingen (San Diego, CA, USA), CD9 (clone CLB-thromb/8,4E1) and CD63 (clone CLBGran/12) from Immunotech (Marseille, France), CD21 (clone 1F8) from DakoCytomation (Glostrup, Denmark) and CD37 (clone HH1) from DIATEC AS (Oslo, Norway). Stained cells were analyzed in a FACSCalibur flow cytometer using the CellQuest software program (BDB). For those samples that had a low proportion of neoplastic cells (o10% of the whole sample cellularity), as well as in all normal and MGUS samples, a two-step acquisition procedure was performed. In the first step, information was stored on a minimum of 3 Â 10 4 nucleated cells corresponding to the whole sample cellularity. In the second step, acquisition through an electronic 'live gate' was carried out; in normal BM and PB samples, as well as in samples from immature and mature B-cell malignancies, the electronic 'live gate' was drawn on the CD19 þ region in which B-cells are located, while in BM samples from normal individuals, MGUS and MM patients a 'live gate' drawn on the CD38 þ þ þ region was applied in order to specifically select PC. In this second step, information on a minimum of 10 4 CD19 þ B-cells or CD38 þ þ þ , PC was stored. For data analysis, the Paint-A-Gate PRO software (BDB) was used. Expression of tetraspanin molecules was assessed in the following subpopulations of CD19 þ B-cells and/or CD38
For each antigen analyzed, the intensity of expression was evaluated by the mean fluorescence intensity (MFI), observed for the specific cell population under analysis and expressed either as absolute MFI values (arbitrary relative linear units scaled from 0 to 10 4 ) or as a percentage of the maximum MFI observed for that antigen in normal B cells.
Statistical methods and hierarchical clustering analysis
Mean values and their standard deviation, as well as median, range, 25 and 75th percentiles and 95% confidence intervals were calculated for each variable. Statistical analyses were performed with the SPSS 11.0 software program (SPSS Inc., Chicago, IL, USA). For the evaluation of the statistical significance of the differences observed between groups, the Mann-Whitney U-test was used. P values p0.05 were considered to be associated with statistical significance. In B-cell neoplasias, antigen overexpression and underexpression were defined as an MFI higher or lower than the 95% confidence interval observed for its expression in the corresponding normal B-cell counterpart, respectively. Sensitivity and specificity were defined as TP/TP þ FN and TN/TN þ FP, respectively, where TP are true positives, TN true negatives, FN false negatives and FP correspond to false positives.
Hierarchical clustering analysis was performed using those 72 samples in which all markers of the panel had been tested. Clustering was run using standard correlation coefficients; for the cluster method, a similarity metric and average linkage was used. 55 The MFI value obtained for each marker tested was introduced into a dedicated database system (Microsoft Excel, Microsoft, Seattle, WA, USA). A ratio between the MFI obtained for each marker and the mean MFI value obtained for that marker in all normal samples tested was then calculated. Clustering was performed after median centering and normalizing the fluorescence ratios. A logarithmic (base 2) transformation was applied to the values of this ratio for individual data sets. The resulting normalized log 2 ratios were used for further statistical analyses with the J-Express Pro V2.1 software (MolMine AS, Bergen, Norway).
In order to explore the predictive value of the normal patterns of expression of tetraspanins and other related molecules, to properly classify neoplastic B cells according to their stage of maturation arrest, a class predictor was built using a weighted voting algorithm evaluated with a leave-one-out cross validation. For this purpose, a training set of normal B-cell populations (n ¼ 20) grouped into three classes was used: (1) normal BM BCP; (2) normal mature BM, PB and lymph node B-lympho-cytes; and (3) normal BM PC. The accuracy of the predictor was then tested in a set of 51 neoplastic populations of B cells using the nearest shrunken centroids method (PAM software; details may be found at http://www-stat.stanford.edu/~tibs/PAM). 56 
Results
Expression of tetraspanin antigens and other related molecules during normal B-cell maturation
In normal BM, three subpopulations of CD19 þ B cells were identified by their differential expression of the CD10 and CD34 antigens. These subsets corresponded to three stages of increasingly mature B-cells:
þ , and III) CD34 À /CD10 À (Figure 1 ). In addition, normal PC were also identified in control BM samples by their extremely high CD38 expression. Mature B lymphocytes from both PB and reactive lymph node samples were also studied.
The relative expression of all tetraspanin antigens changed during normal B-cell development, except CD63Fwhich was always detected at very low levels on the surface of all B-lineage cells (Figures 1 and 2) . Accordingly, the early CD34
and late CD34 À /CD10 þ BCP displayed relatively high levels of CD9 and CD81, but barely detectable amounts of CD37 and CD53; as these cells differentiated into CD10
À B cells, a significant reduction of CD9 and CD81 expression towards undetectable amounts was observed, in association with a dramatic increase in the levels of surface CD37 and CD53. Interestingly, CD10
À /CD34 À B-lymphocytes in the BM and B lymphocytes from both normal PB and reactive lymph nodes showed a similar pattern of tetraspanin expression: high reactivity for CD53 and CD37 and dim/negative expression of CD81 and CD9. In turn, PC that have recirculated from lymphoid tissues back to the BM, lost expression of CD37 and regained reactivity for CD9, dissociating their expression from CD53 and CD81, respectively.
Expression of tetraspanin antigens and other related molecules in neoplastic B cells
In general, a parallel expression of individual tetraspanin molecules was found in normal and neoplastic B cells. Despite this, significant differences existed between the two groups ( Figure 2) .
Concerning BCP-ALL (left columns from all panels in Figure 2 ) variable levels of most tetraspanin antigens were detected in both the CD34 þ and CD34 À patient groups. However, as compared to normal CD34 À /CD10 þ BCP, CD34 À BCP-ALL cases showed overexpression of both CD37 (P ¼ 0.05) and CD53 (P ¼ 0.05) while CD34 þ BCP-ALL displayed a significantly reduced CD81 (P ¼ 0.003) expression and higher reactivity for CD63 (P ¼ 0.005) in comparison with normal CD34 þ BCP. No additional significant differences were observed in either group, regarding the expression of other tetraspanin molecules. Table 1 shows the exact percentage of BCP-ALL cases showing abnormally high and low amounts of each of the proteins analyzed.
Among mature/peripheral chronic B-cell leukemias and nonHodgkin's lymphomas (middle-left columns from all panels in Figure 2 ), a pattern of expression of tetraspanin molecules similar to that of normal mature PB and lymph node B-lymphocytes, was observed. Despite this, abnormal expression of specific antigens was found in several individual diagnostic subgroups (summarized in Table 1 ). Accordingly, in B-CLL/PLL cases, identical patterns of expression of tetraspanin molecules were observed as those found for normal mature circulating B-lymphocytes, with low CD9 and CD81 expression and strong reactivity for CD37 and CD53. In spite of this, B-CLL/ PLL patients showed aberrantly low levels of CD81 (P ¼ 0.004) and CD37 (Pp0.001) and abnormally high amounts of CD53 (P ¼ 0.005) as compared to normal PB B cells. Interestingly, among B-CLL cases, aberrantly increased expression of CD53 and decreased reactivity for CD9 correlated with the pattern of in vivo tissue distribution of neoplastic B cells. Accordingly, increased reactivity for CD53 was associated with a higher frequency of lymph node involvement (P ¼ 0.02) and greater PB lymphocytes counts (P ¼ 0.02), while cases with decreased expression of CD9 showed a more pronounced BM infiltration (P ¼ 0.03) and lower PB platelet counts (P ¼ 0.02).
In a similar way, although B-NHL generally displayed a similar profile of tetraspanin molecule expression as normal circulating PB/lymph node B cells, a significantly higher expression of CD53 was observed in MALT/SZML patients (P ¼ 0.05). Although only two HCL were studied, both displayed an almost identical tetraspanin immunophenotype with aberrantly high expression of CD53 and CD63, with respect to both normal mature B lymphocytes and PC (Figure 2) .
Clonal PC from patients with MGUS and MM (right columns in all panels in Figure 2) , showed a rather similar pattern of tetraspanin antigen expression. Once compared to normal B cells, this pattern was more closely related to that of normal BM PC. Nevertheless, clonal PC from MM showed significantly reduced CD9 expression (P ¼ 0.01), as compared to their normal counterparts. Another striking characteristic of tetraspanin antigen expression in clonal PC relates to the higher amounts of CD63 detected in MGUS as compared to normal (P ¼ 0.09) and MM (P ¼ 0.03) PC, which were at least twenty-fold over those detected in any normal B cells. Figure 2 . Arrows indicate the location of changes in the pattern of tetraspanin antigen expression. The levels of expression of surface CD63 (data not shown) were always low and similar in all maturation stages analyzed, except in plasma cells (see Figure 2) . PB: peripheral blood. PC: plasma cells.
Tetraspanin antigen switch in B-cell neoplasias S Barrena et al
Abnormally high expression of the CD21 tetraspanin-associated molecule was found in both CD34 À (P ¼ 0.02) and CD34 þ (P ¼ 0.007) BCP-ALL and MM (P ¼ 0.01). In turn, significantly reduced levels of CD19 were detected in MALT/SMZL (P ¼ 0.01), MCL (P ¼ 0.02), MGUS (P ¼ 0.03) and MM (P ¼ 0.03), as well as in a significant proportion (41%) of all B-CLL patients (Tables 1  and 2 ). In contrast, the pattern of expression of HLADR was similar in neoplastic B cells and their normal counterparts.
Classification of B-cell neoplasias according to the expression of tetraspanin and tetraspanin-associated antigens
Multivariate analysis of flow cytometry data was initially performed using tools that are usually employed for the analysis of microarray gene expression, although in this study the values reflect protein rather than RNA levels. Results of this analysis are Tetraspanin antigen switch in B-cell neoplasias S Barrena et al shown in Figure 3 . As it illustrates, similar tumors were clustered together, and at the same time were grouped with the corresponding normal B-cell population, except for two MM cases classified together with immature B cells. Overall, three major groups of B-cell neoplasias were clearly defined: (1) BCP-ALL; (2) mature B-cell neoplasias (B-cell chronic lymphoproliferative disorders plus B-cell NHL); and (3) PC dyscrasias. Their normal counterparts included: (1) CD10 þ BM BCP; (2) mature BM, PB or reactive lymph node B lymphocytes; and (3) BM PC. This is a significant finding taking into consideration the low number of markers included in the analysis. Table 1 Frequency of abnormally increased/decreased expression of tetraspanin and tetraspanin-related molecules in B-cell leukemias/ lymphomas 
CD63 MFI
BCP ALL B-CLL/PLL Other B-CLPD MGUS/MM n ¼ 12 n ¼ 29 n ¼ 16 n ¼ 10
Figure 3
Hierarchical cluster analysis of surface expression of five tetraspanin antigens (CD63, CD53, CD9, CD81, CD37) and three tetraspanin-associated proteins (CD19, CD21, HLADR) in normal (n ¼ 20) and neoplastic B cells (n ¼ 52). Mean fluorescence intensity (MFI) values obtained for each antigen by flow cytometry immunophenotyping were imported and analyzed. Rows represent the individual subpopulation of B cells analyzed from both normal and neoplastic samples and columns represent the normalized log 2 ratios of the MFI obtained for each marker divided by the mean MFI value obtained for that marker in all normal samples tested, for each protein analyzed. The relative level of expression of each molecule is represented in a color code: red represents expression greater than the mean, green represents expression lower than the mean and the color intensity represents the magnitude of the deviation from the mean; as indicated, the scale extends from ratios of À6.678 to þ 6.678 (log 2 units).
Table 2
Clinical and biological characteristics of B-CLL patients associated with the pattern of expression of tetraspanin molecules 
Tetraspanin antigen switch in B-cell neoplasias S Barrena et al
In order to investigate the predictive value of the patterns of expression of tetraspanin and other related molecules during normal B-cell maturation, a supervised prediction model was built to identify three classes: (1) BM BCP; (2) mature BM, PB and lymph node B lymphocytes; and (3) BM PC. For this purpose a training set which included all normal B-cell populations (n ¼ 20) and a leave-one-out crossvalidation scheme were used. The predictor contained eight phenotypic variables and assigned the withheld sample to the appropriate class with 100% accuracy. Once this model was tested with the neoplastic samples (n ¼ 51) it showed an overall accuracy of 88%, the percentage of correctly classified samples ranging from 70% of the PC dyscrasias to 100% of all mature B-cell leukemias and lymphomas. Despite this, it should be noted that combined use of the five tetraspanin and three tetraspanin-associated molecules studied here allowed the specific (100% specificity) distinction between normal and neoplastic B cells with a sensitivity ranging from 20% in PC dyscrasias and 69% in B-cell chronic lymphoproliferative disorders other than B-CLL to 100% in both BCP-ALL and B-CLL.
Discussion
Analysis of the reactivity for the CD9, CD37, CD53 and CD81 tetraspanin antigens showed the occurrence of important changes in their expression during normal B-cell maturation. Accordingly, our results show the existence of three different combinations of tetraspanin expression during B-cell maturation: CD9/CD81 in the early BM BCP, CD37/CD53 in mature/ peripheral B lymphocytes, and CD9/CD53 in PC that have passed through secondary lymphoid tissues and reentered the BM.
Among other processes, tetraspanins are involved in cell adhesion. 57, 58 Thus, the observation of distinct patterns of tetraspanin expression during B-cell maturation may reflect the occurrence of different cellular interactions and homing properties. In line with this hypothesis, the more mature BM B lymphocytes lost CD9 and CD81 when they got ready to migrate and leave the BM. These findings are in line with previous observations in carcinomas, where loss of any of these proteins has been shown to correlate with a worse prognosis, 8 associated with a higher metastatic potential. The molecular basis of the differential pattern of tetraspanin expression remains unknown, since of the four antigens mentioned, only the promoters of the CD9 59 and CD53 genes 60 have been partially characterized. Alternative gene expression of CD9, CD37 or CD53 has also been detected in different types of renal 61 and prostate carcinomas. 62 The expression of at least three different combinations of tetraspanin antigens during normal B-cell maturation suggests that distinct patterns of expression of these proteins might also be found in B-cell neoplasias. Overall, the analysis of the pattern of expression of the four tetraspanin antigens indicated that there is a relatively high degree of correlation between normal and neoplastic cells, and that the tumors can be classified according to their putative stage of maturation arrest based on the pattern of tetraspanin expression. Accordingly, mature/peripheral B-cell leukemias and lymphomas tended to express high levels of CD37 and CD53, while those derived from BCP-ALL and clonal PC coexpressed CD9 with either CD81 or CD53, respectively. Based on these markers, only two MM cases showing the highest amounts of CD81 on PC were misclassified. Despite these phenotypic similarities, neoplastic B-cells showed variable levels of expression of one or more of these proteins that were frequently expressed at abnormally low or high amounts per cell. Interestingly, some of these phenotypic aberrations were common to most patients within a specific disease group. In fact, CD81 was aberrantly underexpressed in virtually all B-CLL cases and in up to 75% of BCP-ALL patients; in turn, CD63 was overexpressed in around three quarters of all BCP-ALL and B-CLL patients. An intriguing finding regarding CD63 expression is its upregulation on MGUS, but not on myelomatous PC, in comparison to normal PC. CD63 is mostly an intracellular antigen present on the membrane of endosomes and other intracellular vesicles that becomes expressed on the cell surface after degranulation.
63,64 Interestingly, we have recently shown that clonal PC from MGUS but not MM show an increased surface expression of HLA-I molecules; 65 further investigations are required to clarify the potential relationship between the increased HLA-I and CD63 expression on clonal PC from MGUS. Altogether, these results point out the utility of these tetraspanin molecules in combination with other B-cell-associated markers, not only for the diagnostic classification of B-cell neoplasias but also for the identification of aberrant phenotypes that could be used for monitoring minimal disease levels. 54, 66, 67 Although the exact significance of such phenotypic aberrations still needs to be established, they might reflect specific genetic abnormalities. In fact a careful comparison of B-CLL/PLL cases with 13q-(n ¼ 6) and those who did not have these abnormalities (n ¼ 14) showed that the intensity of expression of CD21 was significantly higher in the former group of patients (MFI of CD21: 58740 vs 26726; P ¼ 0.05). However, due to the relatively limited number of cases included in each specific cytogenetic category in most diagnostic groups, definitive conclusions about these phenotypic/genotypic associations require further study in larger groups of patients. Nevertheless, it should be noted that once a well-characterized diagnostic entity such as B-CLL was considered the pattern of expression of CD9 and CD53, tetraspanins were associated with the pattern of in vivo tissue involvement. Accordingly, abnormally high reactivity for CD53 was associated with greater PB and lymph node infiltration. Previous studies have shown that ligation of CD53 antigen protects lymphoid cells from apoptosis, 17 an important property for mature/peripheral memory lymphocytes. Accordingly, overexpression of CD53 could render B-CLL cells more adapted to survive in PB and lymph nodes. In contrast, decreased CD9 expression on B-CLL cells was related to a higher BM involvement and decreased numbers of platelets in PB. CD9 has been shown to function as a motility/ migration brake when reintroduced in some carcinoma cells. 9 At the same time it has been associated with a higher metastatic potential, 8 which could help to explain the relationship observed between CD9 expression and the pattern of BM involvement.
In summary, in the present study, we show that during normal B-cell maturation there are two switches in tetraspanin antigen expression occurring in the BM, in the transition from CD10 þ BCP to CD10-B lymphocytes, and later on during terminal differentiation into antibody-secreting BM PC. Interestingly, the pattern of tetraspanin antigen expression on the surface of neoplastic B cells shows great similarities to their normal counterpart allowing discrimination between different B-cell neoplasms. Despite this, neoplastic B cells frequently show aberrant expression of specific tetraspanin molecules that could be used for the investigation of minimal disease.
